Jennifer A. Woyach

Professor and hematologist-oncologist, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center

Appears in 1 story

Stories

FDA approves Jaypirca for previously untreated CLL/SLL

New Capabilities

Active in CLL research and BTK inhibitor trials

The FDA on October 2 approved Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, making it the first non-covalent BTK inhibitor available as initial therapy. The approval covers adults with previously untreated CLL or small lymphocytic lymphoma who lack a 17p deletion, a subgroup that makes up roughly 92% to 95% of new cases.

Updated 2 hours ago